Precision BioSciences (NASDAQ:DTIL – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Wednesday, March 26th. Analysts expect Precision BioSciences to ...

PRECISION BIOSCIENCES ($DTIL) is expected to release its quarterly earnings data on Tuesday, March 25th after market close, per Finnhub. Analysts are expecting ...

In other Precision BioSciences news, CEO Michael Amoroso sold 36,838 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $4.67 ...

Precision BioSciences (DTIL) announced the presentation of preclinical data for its PBGENE-DMD development program for the treatment of ...

DURHAM, N.C., March 19, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...

Ratings for Precision BioSciences (NASDAQ:DTIL) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments ...

Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...

Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and has secured strategic partnerships for azer-cel's development in cancer ...

To apply a precision medicine approach to this disease, Character Bio has partnered with over 150 ophthalmology treatment ...

Analysts have set 12-month price targets for Precision BioSciences, revealing an average target of $53.5, a high estimate of $60.00, and a low estimate of $34.00. Staying constant with the previous ...